Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cystic Fibrosis
91%
Pediatrics
47%
Ivacaftor
23%
Tezacaftor
23%
Pseudomonas aeruginosa
23%
Diseases
23%
Adolescence
23%
Silo-Filler's Disease
21%
Prematurity
20%
Prevalence
19%
Bronchiolitis
18%
Infection
15%
COVID-19
14%
Lung Transplantation
14%
Primary Ciliary Dyskinesia
14%
Asthma
14%
Lung Clearance
12%
Spirometry
12%
Pneumonia
11%
Respiratory Tract Infection
11%
Body Mass Index
11%
Sputum Culture
10%
Lung Function Test
10%
Nitric Oxide
10%
Palivizumab
10%
Lung
10%
Forced Expiratory Volume
9%
Patient Registry
9%
Human Respiratory Syncytial Virus
9%
Duchenne Muscular Dystrophy
9%
Tracheoesophageal Fistula
9%
Bronchodilating Agent
8%
Lung Dysplasia
8%
Emergency Department
8%
Patient with Cystic Fibrosis
8%
Intensive Care Unit
8%
Carbon Dioxide
7%
Lung Function
7%
Corticosteroid
7%
Chloride
7%
Deterioration
6%
Quality of Life
6%
Breathing
6%
Disease Predisposition
6%
Morbidity
6%
Retrospective Study
6%
Neonate
6%
Wheeze
6%
Purpura
6%
Intensive Care
6%
Keyphrases
Cystic Fibrosis
100%
Israel
29%
Elexacaftor-tezacaftor-ivacaftor
28%
COVID-19
23%
Respiratory Syncytial Virus
19%
Bronchiolitis
17%
Palivizumab
16%
Forced Expiratory Volume in 1 Second (FEV1)
16%
Respiratory Infection
15%
Pseudomonas Aeruginosa (P. aeruginosa)
14%
Respiratory Syncytial Virus Bronchiolitis
14%
National Survey
14%
Extremely Premature Infants
14%
Lung Transplantation
12%
Risk Factors
12%
Lung Clearance Index
12%
Spirometry
11%
Bronchopulmonary Dysplasia
11%
Pulmonary Exacerbation
11%
Randomized Placebo-controlled Trial
10%
Fever
10%
Pediatric
10%
Intravenous Immunoglobulin (IVIg)
10%
Face Mask
10%
Pulmonary Function Test
9%
Patient Registry
9%
Pulmonary Outcomes
9%
Lactic Dehydrogenase
9%
Post-infection
9%
Isoenzymes
9%
Guillain-Barré Syndrome
9%
Preconception Carrier Screening
9%
Cerebrospinal Fluid
9%
Duchenne muscular Dystrophy
9%
Treatment Effect
9%
Primary Ciliary Dyskinesia
9%
Neonate
9%
Israeli
9%
Age at Diagnosis
9%
Hospitalization
9%
Lung Disease
8%
Sputum
8%
Desaturation
7%
Medical Center
7%
Gestational Age
7%
Disease Severity
7%
Presenting Symptoms
7%
Screening Program
7%
Young children
7%
Lumacaftor/ivacaftor
6%
